About TriAltus Bioscience
TriAltus Bioscience is a company based in Birmingham (United States) founded in 2017 by Dmitry Vassylyev and Bob Shufflebarger. TriAltus Bioscience has raised $1.58 million across 3 funding rounds from investors including HHS and Innovate Alabama. TriAltus Bioscience operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Birmingham, United States
- Founders Dmitry Vassylyev, Bob Shufflebarger
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website trialtusbioscience.com
- Social LinkedIn X Facebook
- Legal Name Trialtus Bioscience, Llc
- Total Equity Funding$1.58M (USD)
in 3 rounds
- InvestorsHHS
& 1 more
Funding Insights of TriAltus Bioscience
TriAltus Bioscience has successfully raised a total of $1.58M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.58M
- Total Rounds 3
- First Round $1.58M
(Apr 2019)
- Investors Count 2
All 3 funding rounds of TriAltus Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | – | Grant | – | – | |
| Sep 2021 | $256,571 | Grant | – | – | |
| Apr 2019 | $1.58M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in TriAltus Bioscience
TriAltus Bioscience has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Innovate Alabama.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Innovate Alabama is focused on fostering innovation and economic growth. | – | innovatealabama.org | Birmingham, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for TriAltus Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TriAltus Bioscience
3 people are tracked at TriAltus Bioscience (3 in leadership).
| Name | Role | Group |
|---|---|---|
Dmitry Vassylyev | Co-Founder & CSO | Leadership |
Bob Shufflebarger | Co-Founder & CEO | Leadership |
Tom Round | Vice President, Business Development | Leadership |
Complete people profiles for TriAltus Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TriAltus Bioscience
3 dated milestones of TriAltus Bioscience across 5 years, from founding to its latest funding, stage changes and deals.
- Founded TriAltus Bioscience is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Grant,.
Competitors of TriAltus Bioscience
TriAltus Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| arzeda.com | 2008 | Seattle, United States | $94.96M | 66 | Synthetic enzymes are designed using computational technology for industrial applications. | |
| aalphabio.com | 2017 | Seattle, United States | $45.24M | 48 | Developer of cell-based tool for the measurements of protein interactions | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of TriAltus Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TriAltus Bioscience
The website of TriAltus Bioscience (trialtusbioscience.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 4.1% vs previous month
Websites whose visitors overlap most with TriAltus Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| antibodies-online.com | 100% | 57.4K | #648,443 | View details | |
| cytivalifesciences.com | 100% | 312.5K | #148,975 | View details | |
| cytoskeleton.com | 94% | 25.6K | #1,134,849 | View details | |
apexbt.com | apexbt.com | 94% | – | #441,822 | – |
| genscript.com | 80% | 456.1K | #94,888 | View details |
Latest news on Trialtus Bioscience
Complete news archive for TriAltus Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to TriAltus Bioscience
10 companies that operate in the same segment as TriAltus Bioscience (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TriAltus Bioscience
TriAltus Bioscience was founded in 2017 and raised its 1st funding round 2 years after it was founded.
TriAltus Bioscience is headquartered in Birmingham, United States. It is registered at Birmingham, Alabama, United States.
Bob Shufflebarger is the current CEO of TriAltus Bioscience. They have also founded this company.
TriAltus Bioscience is a funded company, having raised a total of $1.58M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.58M, raised on Apr 2019.
TriAltus Bioscience was founded in 2017 in Birmingham, United States, within the bioscience sector. The CL-7 protein purification technology platform was licensed from the University of Alabama at Birmingham to support structural analysis of proteins and industrial-scale production. Products including sumo protease, precision protease, and IM7 activated resin are offered to facilitate these operations.
TriAltus Bioscience's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
TriAltus Bioscience has 2 investors. Key investors include HHS, and Innovate Alabama.
TriAltus Bioscience operates through Trialtus Bioscience, Llc.